Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin, Docetaxel, and Pegfilgrastim for Locally Advanced or Inflammatory Breast Cancer
NCT00066443Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2003
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of epirubicin, docetaxel and pegfilgrastim in breast cancer (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Toxic effects at 7 years and Response (phase II) at 12 years. Started Nov 2003; status: completed.
02
Drugs
epirubicindocetaxelpegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00066443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066443.